Qiagen略微错过了对收入的预期,导致分析家的反应不一。 Qiagen slightly misses earnings expectations, causing mixed reactions from analysts.

生命科学公司Qiagen将其2025财政年度收入指南更新为2.28 EPS,略低于分析师预计的2.35美元。 Qiagen, a life sciences company, updated its FY 2025 earnings guidance to $2.28 EPS, slightly below analyst expectations of $2.35. 该公司的2025年Q1指南是0.50 EPS。 The company's Q1 2025 guidance is $0.50 EPS. 分析师意见不一,汇丰银行降级为“持有”和Jefferies重申“买”评级。 Analysts have mixed views, with HSBC downgrading to "hold" and Jefferies reaffirming a "buy" rating. Qiagen的股票的中午交易额升至43.76美元,共识目标为50.07美元。 Qiagen's stock saw a midday trading boost to $43.76, with a consensus target of $50.07. 该公司为生物样本的加工提供了解决办法,市场上限为97.1亿美元。 The company offers solutions for processing biological samples and has a market cap of $9.71 billion.